Carolina Urologic Research Center

Running trials

• Not yet recruiting

  A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

  NCT07827612· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  NCT07723248· Phase 3· ORIC Pharmaceuticals· Source

• Recruiting

  A Study of GEN1106 in Participants With Solid Tumors

  NCT07416123· Phase 1· Genmab· Source

• Recruiting

  Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

  NCT07543757· Sequenom, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

  NCT07475806· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06842498· Phase 2· Kyntra Bio· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT07190300· Phase 1/2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

  NCT07222488· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07244341· Phase 1· Daiichi Sankyo· Source

• Enrolling by invitation

  A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

  NCT07218003· Phase 1· Rondo Therapeutics· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Pfizer· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

  NCT06774131· Phase 3· UroGen Pharma Ltd.· Source

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· Phase 2· Tyra Biosciences, Inc· Source

• Recruiting

  A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

  NCT06971614· Phase 2· ImmVira Pharma Co. Ltd· Source

• Active, not recruiting

  64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

  NCT06970847· Phase 3· Clarity Pharmaceuticals Ltd· Source

• Recruiting

  Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT06801236· Phase 1· Acerand Therapeutics (Hong Kong) Limited· Source

• Recruiting

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  NCT06800313· Phase 1/2· Janssen Research & Development, LLC· Source

• Recruiting

  Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

  NCT06613100· Phase 1· Amgen· Source

• Recruiting

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Pfizer· Source

• Recruiting

  FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

  NCT06636682· Phase 2· Cellvax Therapeutics Inc· Source

• Recruiting

  A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

  NCT06545955· Phase 3· Ferring Pharmaceuticals· Source

• Recruiting

  Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06510374· Phase 3· Ferring Pharmaceuticals· Source

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· CG Oncology, Inc.· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

  NCT06235151· Phase 3· Curium US LLC· Source

• Recruiting

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  NCT06225596· Phase 2· BicycleTx Limited· Source

• Recruiting

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· Phase 3· Clarity Pharmaceuticals Ltd· Source

• Active, not recruiting

  A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

  NCT06111235· Phase 3· CG Oncology, Inc.· Source

• Recruiting

  Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

  NCT06134232· Phase 2· Dendreon· Source

• Recruiting

  Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

  NCT05951179· Phase 2· Protara Therapeutics· Source

• Recruiting

  A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

  NCT05710848· Phase 1/2· SURGE Therapeutics· Source

• Active, not recruiting

  Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

  NCT05683691· Francis Medical Inc.· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  NCT05614739· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

  NCT05483868· Phase 1· Aura Biosciences· Source

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Janssen Research & Development, LLC· Source

• Recruiting

  ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  NCT05059444· Guardant Health, Inc.· Source

Showing 50 of 74.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer21 recruiting
• Bladder cancer18 recruiting
• Kidney cancer3 recruiting
• Lung cancer3 recruiting
• Gastric and oesophageal cancer2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

  NCT06331299· Phase 3· UroGen Pharma Ltd.· Source

• Completed

  A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

  NCT06395753· Phase 2· Debiopharm International SA· Source

• Completed

  Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

  NCT06235099· Phase 3· Curium US LLC· Source

• Completed

  A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

  NCT06181266· Phase 1· Prokarium Ltd· Source

• Completed

  Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

  NCT05085990· Phase 1· Protara Therapeutics· Source

• Terminated

  Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

  NCT05617040· Phase 1/2· Barinthus Biotherapeutics· Source

• Completed

  Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

  NCT05605964· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Sumitomo Pharma America, Inc.· Source

• Completed

  64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

  NCT05407311· Phase 2· Clarity Pharmaceuticals Ltd· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

  NCT05085977· Phase 1· Protara Therapeutics· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Sunnybrook Health Sciences Centre· Source

• Completed

  XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT05005728· Phase 2· Xencor, Inc.· Source

• Terminated

  LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

  NCT04690699· Phase 1/2· Istari Oncology, Inc.· Source

• Completed

  Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

  NCT04666129· Phase 1· Sumitomo Pharma America, Inc.· Source

• Completed

  A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

  NCT03914794· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Terminated

  Study of ORIC-101 in Combination With Enzalutamide

  NCT04033328· Phase 1· ORIC Pharmaceuticals· Source

• Completed

  STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

  NCT03988309· Pacific Edge Limited· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Astellas Pharma Global Development, Inc.· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer91 works · 54 trials